- Home
- MAX vs FBRX Comparison
MAX vs FBRX Comparison
Compare MAX & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAX | FBRX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.4M | 487.2M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MAX | FBRX |
|---|---|---|
| Price | $8.48 | $21.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $12.70 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 597.2K | 193.6K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.81 | ★ 61.30 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,113,600,000.00 | $36,000.00 |
| Revenue This Year | $13.42 | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | $39.48 | ★ N/A |
| Revenue Growth | ★ 28.78 | N/A |
| 52 Week Low | $7.09 | $7.78 |
| 52 Week High | $13.92 | $35.80 |
Technical Indicators
Market Signals| Indicator | MAX | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 38.19 |
| Support Level | $8.23 | $10.38 |
| Resistance Level | $10.45 | $22.61 |
| Average True Range (ATR) | 0.40 | 2.15 |
| MACD | -0.04 | -0.41 |
| Stochastic Oscillator | 35.44 | 24.86 |
Price Performance
Historical ComparisonAbout MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.